Impact of achieving glycated hemoglobin targets on cardiovascular events/mortality: Post-hoc analysis of the nephropathy in diabetes type 2 trial

Figure 1 Kaplan-Meier curves according to glycated hemoglobin target. Curves for major adverse cardiovascular events: A: In the multifactorial intensive therapy (MT) group [glycated hemoglobin (HbA1c) at target: Yes = 119; No = 65]; B: In the standard of care (SoC) group (HbA1c at target: Yes = 60; No = 79); Curves for all-cause mortality: C: In the MT group (HbA1c at target: Yes = 119; No = 65); D: In the SoC group (HbA1c at target: Yes = 60; No = 79). In each panel, red curves indicate patients not at HbA1c target, and blue curves indicate patients at HbA1c target within the corresponding therapy group. MT: Multifactorial intensive therapy; SoC: Standard of care.